Ann: Clinical milestones for 2024 & 2023 successes highlighted, page-9

I speculate, due to just 1/10 shares on issue compared to IMU and a similar pathway to get the first tech, CHM 1101vs Azer-Cel, approved, that CHM should run higher than IMU. But if the CF33 application data prove what's already been said between the lines then IMU will be shot up sky high. I hold 3 x more CHM than IMU but as outlined above it is hard to tell which one runs first. Best scenario, one runs like crazy, then switching into the other one. Worst case, both go down the drain.

Should IMU sell one of its assets soon, as the CEO let slip out recently, then CHM should benefit from it too, signalling to the market that Hopper got his Mojo back and his strategies work.

No definite answer, all pure speculation.

GLTA